Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aetna's Closed Part D Formulary Limits Drug Access, CMS Says

Executive Summary

Drug access problems stemming from Aetna's change in 2010 from an open formulary to a more restrictive closed one in many of its Medicare Part D plans has drawn sanctions from the Centers for Medicare and Medicaid Services

You may also be interested in...



Medicare Part D News In Brief

Part D status in MedPAC report to Congress: Ninety percent of Medicare beneficiaries had some sort of prescription drug coverage as of January 2010, the Medicare Payment Advisory Commission says in its annual report to Congress, released March 1. The report includes a discussion of the status of Part D, where it is noted that among Medicare beneficiaries, 59 percent receive drug benefits through a Part D drug plan and 32 percent have drug coverage that is at least as generous as Part D through an employer or other source. While the number of stand-alone drug plans declined 7 percent in 2010, beneficiaries in each coverage region still have from 41 to 55 plan choices; 317 premium-free plans are available to enrollees who receive the low-income subsidy

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel